Optimizing Aurora Kinase Inhibition in Cervical Cancer: Addressing Challenges and Charting Future Directions

Continued preclinical work on treatment timing, along with translational trials that include correlative analyses, will be essential to fully realize the therapeutic potential of aurora kinase inhibitor–based combinations in cervical cancer (CC).

Despite preclinical evidence supporting Aurora kinase (AURK) inhibitors as rational components of combination therapy for CC, multiple challenges continue to limit their successful clinical integration. A central obstacle is the biological heterogeneity of CC, particularly in the context of HPV-driven oncogenesis. Although Aurora kinase dysregulation is closely linked to HPV oncogene-mediated perturbation of cell-cycle checkpoints, centrosome amplification, and chromosomal instability, dependency on AURKA versus AURKB varies substantially across tumors (15). AURKA amplification is observed only in a subset of CC cases, and its prognostic and predictive significance remains incompletely defined, complicating patient selection (166). Similarly, while AURKB overexpression correlates with poor prognosis and aggressive proliferation, not all tumors exhibit functional reliance on AURKB activity, underscoring the necessity of molecular stratification (57).

Key Challenges in Aurora Kinase Inhibition for Cervical Cancer

1. Therapeutic Resistance

Therapeutic resistance represents a further major challenge. Both intrinsic and acquired resistance to AURK inhibitors have been documented across cancer types and are likely seen in CC. Resistance frequently emerges through compensatory activation of survival pathways, including PI3K/AKT, MAPK, and spindle assembly checkpoint regulators, which preserve cell viability despite mitotic disruption (131).

2. Pharmacologic Limitations of Current AURK Inhibitors

Pharmacologic limitations of current AURK inhibitors further restrict their clinical utility. Agents such as Alisertib and Barasertib exhibit narrow therapeutic indices, with dose-limiting hematologic toxicities arising from on-target effects in proliferating normal tissues (167). These toxicities are often worsened when AURK inhibitors are combined with cytotoxic chemotherapy, complicating dose optimization and treatment tolerability. In addition, limited isoform selectivity and overlapping inhibition of AURKA and AURKB contribute to off-target effects (66). Although next-generation inhibitors with improved selectivity have been developed, their efficacy in CC remains largely unexplored. Clinical translation of Aurora kinase inhibitors has also been constrained by pharmacokinetic and therapeutic exposure limitations. Early-generation Aurora kinase inhibitors frequently demonstrated pharmacologic challenges, including dose-limiting toxicities that complicate sustained target inhibition while minimizing systemic adverse effects.

The table below summarizes some key pharmacologic challenges associated with specific Aurora Kinase inhibitors:

Advanced nanoparticle-based Aurora kinase formulations such as AZD2811 have therefore emerged as promising approaches to improve pharmacokinetic behavior and toxicity efficacy balance in solid tumors (170).

3. Treatment Scheduling Complexity

Treatment scheduling complexity is another limitation. Preclinical studies demonstrate that the therapeutic efficacy of AURK inhibitors is highly dependent on timing relative to chemotherapy or radiotherapy (171). As a result, control of treatment timing and pharmacodynamic monitoring is required, which may be difficult to apply in routine clinical settings.

Strategies for Enhanced Clinical Integration of Aurora Kinase Inhibitors

These observations emphasize that successful future implementation requires biomarker-guided patient selection, optimized pharmacokinetic properties, improved isoform specificity, and rational combination approaches to maximize efficacy while minimizing systemic toxicities.

1. Biomarker-Guided Patient Selection and Stratification

Priority should be given to CC-specific clinical trials incorporating molecular stratification based on AURKA/AURKB dependency, mitotic instability signatures, and HPV-associated genomic features. Biomarker development is particularly critical, as AURKB expression alone may be insufficient to predict response. Promising candidates include phosphorylation status of Aurora substrates, spindle checkpoint integrity, genomic instability indices, and DNA damage response deficiencies.

2. Rational Combination Strategies

Rational combination strategies represent a key opportunity to overcome resistance and enhance efficacy. Beyond traditional cytotoxic agents, PARP inhibitors, CHK1/ATR inhibitors, WEE1 inhibitors, and targeted agents that disrupt compensatory survival signaling could be used. Combining AURK inhibitors with DNA damage response inhibitors may potentiate mitotic arrest, especially in CC characterized by replication stress and defective DNA repair. These combinations require systematic validation in CC-specific preclinical models followed by biomarker-driven clinical trials. Understanding the critical roles of Aurora kinase A and B in mitosis and cancer progression is fundamental for designing such targeted therapies.

3. Innovative Drug Delivery Approaches

Innovative drug delivery approaches may further improve efficacy. Nanoparticle-based formulations, hydrogel systems, and tumor-targeted carriers offer the potential to improve intratumoral drug accumulation while minimizing systemic toxicity. Targeted delivery strategies guided by HPV-associated epitopes could be particularly advantageous in CC and warrant focused investigation.

4. Addressing the Tumor Microenvironment

The tumor microenvironment also represents an underexplored dimension. HPV-driven CC frequently exhibits immunosuppressive features, including PD-L1 expression and regulatory T-cell infiltration. While AURK inhibitors have demonstrated immunomodulatory effects in other tumor models, their interactions with immune checkpoint blockade in CC remain poorly characterized. Elucidating how AURKB/AURKA inhibition influences antigen presentation, cytokine signaling, and immune infiltration will be essential for designing rational immunotherapy combinations. Future strategies should also consider the evolving landscape of immune checkpoint blockade and how it can be synergistically combined with AURK inhibitors.

5. Global Accessibility Considerations

Finally, given the disproportionate burden of CC in low- and middle-income countries, future strategies must consider global accessibility, emphasizing cost-effective formulations, simplified dosing schedules, and biomarker-guided treatment algorithms to maximize clinical benefit while minimizing unnecessary toxicity.

Conclusion

Aurora kinases play a central role in the regulation of mitosis, chromosomal stability, and cell-cycle progression, and their dysregulation is a recurrent feature of CC driven largely by HPV oncogene activity. Accumulating preclinical and early clinical evidence supports the rationale for targeting AURKA and AURKB as part of combination therapeutic strategies rather than as standalone agents. AZD2811 (also known as AZD2811NP), an advanced nanoparticle formulation of barasertib (AZD1152), stands out as the most promising selective AURKB inhibitor due to its improved pharmacokinetics, favorable toxicity-efficacy profile, and ongoing clinical evaluation in solid tumors. However, the successful clinical integration of aurora kinase inhibitors in CC remains limited by several interrelated challenges, including tumor heterogeneity, variable dependency on specific aurora kinase isoforms, adaptive resistance mechanisms, dose-limiting toxicities, and complex treatment scheduling requirements. Resistance mediated through compensatory survival pathways and checkpoint adaptations further underscores the necessity of rational combination approaches guided by pathway biology. In parallel, the narrow therapeutic window of existing aurora kinase inhibitors such as Barasertib, Danusertib, Alisertib, largely driven by hematologic toxicity, continues to limit dose intensity and durability of response, particularly when combined with cytotoxic chemotherapy.

Taken together, these considerations emphasize that aurora kinase inhibition in CC should be viewed not as a universal strategy, but as a context-dependent therapeutic approach requiring careful patient selection, optimized scheduling, and biologically informed combinations.